For other salt forms please inquire. According to Schwede et al. (2015), Sp-8-BnT-2'-O-Me-cAMPS is the most potent 2'-substituted activator of Epac2 that efficiently discriminates against Epac1 in vitro (AC50 Epac2 = 1.5 μM (1.8 µM for cAMP) and rel. kmax = 4.3 (1 for cAMP)). Due to the 2'-substitution it is an extremely poor PKA activator and thus allows for specific activation of Epac2 over PKA. In human osteosarcoma U2OS cell lines stably expressing Epac1 or Epac2, Sp-8-BnT-2'-O-Me-cAMPS does not induce Epac signalling at 100 µM, which may be due to inefficient cellular uptake in this biosystem. Detailed technical information available. Reference: Schwede et al., PLoS Biol., 13(1): e1002038 (2015) (Link to PLoS Biology).
Related products: Biolog also offers Sp-8-BnT-cAMPS (Cat. No. B 046 / "S-220") which has increased in vitro and in vivo potency compared to Sp-8-BnT-2'-O-Me-cAMPS, but slight potency to activate PKA, as well as the well-established Epac agonist 8-pCPT-2'-O-Me-cAMP (Cat. No. C 041) which selectively activates Epac1 over Epac2 (Schwede et al. 2015).
Cat. No. | B 056 |
Patent Information | The reagent is protected under patent EP 1511757 and foreign equivalents issued or licensed to BIOLOG Life Science Institute. |
CAS number | [pending] |
Purity | > 98% HPLC |
Salt form | Sodium |
Storage temperature | -20°C / -4°F |
Molecular formula | C₁₈H₁₉N₅O₅PS₂ · Na |
Molecular weight [g/mol] | 503.5 |
cAMP modified at the exocyclic oxygen | axial (Sp-) |
Modifications | 8-cAMP, 2'-cAMP |
Target | Epac Activator |
Lipophilicity | 2.87 |
Absorption max [nm] | 283 |
Molar extinction coefficient ε [L·mol⁻¹·cm⁻¹] | 17100 |